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Background: The ever-expanding rollout of antiretroviral therapy in poor resource settings without routine
virological monitoring has been accompanied with development of drug resistance that has resulted in limited
treatment success.
Methods: A cross-sectional study with one time viral load was conducted during the period between 2012 and
2013 to determine treatment failure and drug resistance mutations among adults receiving first-line (44) (3TC_d4T/
AZT_NVP/EFV) and second-line (20) (3TC/AZT/LPV/r) in Nairobi, Kenya. HIV-1 pol-RT genotyping for drug resistance
was performed using an in-house protocol.
Results: A total of 64 patients were recruited (mean age 36.9 yrs.) during the period between 2012 and 2013 of the
44 adult patients failing first-line 24 (40.9%) had drug resistance mutations. Eight (8) patients had NRTI resistance
mutations with NAMS M184V (54.2%) and K65R (8.4%) mutations being the highest followed by TAMs T215Y and
K70R (12.5%). In addition, among patients failing second-line (20), six patients (30%) had NNRTI resistance; two
patients on K103N and G190A mutations while V106A, Y184V, A98G, Y181C mutations per patient were also detected.
However, for NRTI two patients had TAM T215Y. M184V mutation occurred in one patient.
Conclusions: The study findings showed that HIV-1 drug resistance was significantly high in the study population.
The detected accumulated resistance strains show that emergence of HIV drug resistance will continue to be a big
challenge and should be given more attention as the scale up of treatment in the country continues.
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The Kenyan ministry of health began providing antiretro-
viral (ARV) therapy to the public sector in 2003 [1]. Kenya
through the President’s Emergency Plan for AIDS Relief
program, has significantly promoted access to ART [1-3],
with an estimated coverage of 52% (360,000 with CD4
count <350), of the total 694,024 people living with HIV by
the end of 2010. The Kenya government aims to achieve
universal access to ART by targeting 90% (760,316) pa-
tients of the total of 844,795 patients in need of ART, by
the end of 2014 [4].* Correspondence: akibera2000@gmail.com
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unless otherwise stated.Until 2009, the standard first-line regimens were stavu-
dine (d4T) plus lamivudine (3TC) combined with a third
agent: a non-nucleoside reverse transcriptase (RT) inhibi-
tor (NNRTI) in adults and older children or ritonavir-
boosted lopinavir (LPV/r) in young children who had
received nevirapine (NVP) for prevention of mother-to
child transmission (PMTCT) [5,6]. By 2010, the Kenya
government adopted WHO recommendations for early ini-
tiation of ART based on medical criteria and patient’s cap-
acity to treatment adherence (HIV drug resistance report
2010-2011). Stavudine (D4T) was replaced by tenofovir
disoproxil fumarate (TDF) in adults and older children and
abacavir (ABC) in younger children, respectively. Adults
beginning ARV treatment increasingly received TDF rather
than d4T for first-line therapy and children increasingly re-
ceived ABC rather than d4T [7,8].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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potent and cost-effective generic antiretroviral therapies
(ARTs), quality of life has significantly improved, transmis-
sion rates reduced and survival rates increased among
HIV infected individuals [9,10]. However, this benefit is
often limited with development of HIV-1 drug resistance.
Previous studies have shown diverse pathways across dif-
ferent HIV subtypes in development of drug resistance.
This could affect cross-resistance and the potential use of
specific second-line regimens [11]. This concern may be
increased in developing countries where all HIV-1 sub-
types exist while drug resistance reference data is based
HIV-1 subtype B [12].
Although the information on drug resistance patterns
of HIV-1 among treatment-exposed patients is crucial
for the development of novel effective drugs, unfortu-
nately there is no existing system that monitors patterns
of drug resistance in patients failing therapy [13]. This
study was therefore aimed at determining the drug re-
sistance patterns that circulate among patients failing
first and second line drugs and their impact on predicted
treatment options.Methods
Study design and sample collection
Following WHO recommendations [14] a cross-sectional
study was performed and one-time HIV-1 RNA viral load
and CD4 Counts determined among patients who met the
following criteria: confirmed positive HIV status; ≥18 years
old; being on a first-line ART for at least 12 months and
consented to participate in the study. In addition, those
patients failing second-line were also recruited. This
study was approved by Kenya National Ethics Committee
through the Kenya Medical Research Institute (KEMRI)/
National Ethical Review Committee. During the period
of March 2012 and March 2013, patients were consecu-
tively enrolled from KEMRI/KNH HIV comprehensive
clinics centre. This is one of the referral centres for drug
resistance testing in the country that manages approxi-
mately ≥1000 patients.
A standardized questionnaire was used to collect demo-
graphic data that included age, sex, ARV use (name, and
switch), education levels, marital status and drug adher-
ence. Those patients who had treatment interruptions at
the time of blood sampling were excluded from the study.
Additionally, patients who transferred from other treat-
ment clinics and those who defaulted but came back for
treatment later were also excluded from the study. In
addition, participants with a previous history of ART ex-
posure for prevention of mother to child transmission
(PMTCT) or for post-exposure prophylaxis (PEP) were
excluded from the study. Three ml of blood samples were
collected from each participant for routine CD4 countcounts and the remnants centrifuged to obtain plasma, for
viral load quantification and HIVDR testing.
HIV-1 RNA quantification and CD4 counts
CD4 T cell counts were performed using a FACSCalibur
flow cytometer (Becton-Dickinson, NJ) and expressed in
absolute count [3]. Individual test results were reviewed
to confirm the accuracy of the automated software ana-
lysis. Viral loads were determined using NucliSens EasyQ
(Biome’rieux, Marcy l’Etoile, France), with a lower limit of
quantitation of 50 (1.69 log10) copies/ml of plasma, ac-
cording to the manufacturer’s instructions. This was done
to confirm virological failure (above 1000 copies/ml) be-
fore drug resistance testing was performed [6].
PCR and sequencing
Whole blood samples from patients failing first and sec-
ond line ART were obtained and separated to obtain
Peripheral blood mononuclear cells (PBMCs) by Ficoll-
Hypaque density gradient centrifugation. Proviral DNA
was extracted from the PBMCs using DNAzol (GIBCO
BRL, Life Technologies) lysis and ethanol precipitation.
Nested polymerase chain reaction (PCR) was performed
using AmpliTaq Gold (Roche Molecular Systems, Branch-
burg, NJ). Briefly, HIV- 1 pol gene was amplified using the
primers (RT18:5′GGAAACCAAAAATGATAGGGGGAA
TTGGAGG3′ and RT21 5′ CTGTATTTCTGCTATTAA
GTCTTTTGATGGG 3′) and second round primers (RT
1: 5′ CCAAAAGTTAAACAATGGCCATTGACAGA 3′
and RT4: 5′ AGTTCATAACCCATCCAAAG 3′) in the
second round [15]. Amplification was achieved using
1 cycle of 95°C for 10 min and 35 cycles of 95°C for 30 s,
60°C for 30 s, and 72°C for 1 min, with a final extension of
72°C for 10 min [3] PCR amplification was confirmed by
visualization with ethidium bromide staining of the gel.
Positive generated amplicons were then directly se-
quenced using Big Dye technology on ABI 310 (Applied
Biosystems, Foster City, CA) [16].
Genotypic drug resistance analysis and HIV subtyping
Genotypic drug resistance in the pol-RT region was de-
fined as the presence of one or more resistance-related
mutations, as specified by the consensus mutation fig-
ures of the International AIDS Society-USA [3]. HIV
subtyping tools, genotype (http://www.ncbi.nlm.nih.gov/
projects/genotyping/formpagex.cgi), RIP (http://www.hiv.
lanl.gov/content/ sequence/RIP/RIP.html), and Jumping
HMMER (http://jphmm.gobics.de/submission_hiv.html),
were used in confirming subtyping [16].
Results
Demographic characteristics
A total of sixty four (64) patients failing first-line 44
(67.2%) and second line 20 (32.8%) therapy were evaluated.
Table 1 Baseline characteristics of HIV-1 infected Kenyan
patients at enrolment
Gender







Mean 230 207 243
Range (1-628) (5-584) (1-628)






WHO Disease staging P > 001
WHO Stage 1 9 7 2
WHO Stage 2 23 11 12
WHO Stage 3 24 12 12








First-line 42 21 21
Second-line 18 9 9
Education levels
Primary 14 8 6 P > 0.001
secondary 22 9 13
College/Tertiary 21 8 13
None 2 1 1
Marital status
Single 5 3 2 P > 0.841
Married 49 20 29
Separated/Divorced 5 4 1
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an average age of 37 yrs. Thirty (46.2%) were female and
34 (63.8%) males with all being residents of different re-
gions of Nairobi. Data on length of time on the failing regi-
men was not available.
Virological and immunological failure
Immunological and virological failure was determined
by use of CD4 count (>350 cells/ml) and viral load
(>1000 HIV RNA copies/ml). We determined whether
age, marital status, WHO disease stage and education
levels influenced virological and/or immunological fail-
ure (Table 1).
Drug resistance
WHO recommends two NRTIs and one NNRTI for first
line drugs with a switch to protease inhibitor for a
second-line therapy (Table 2). In this study, most patients
on first-line ART were on Nevirapine (40.6%) containing
regimens followed by Efavirenz 18(27.7%) combination
with those on second-line being on Lopinavir (30.1%) con-
taining regimen (Table 2). However, drug combinations
among patient on first-line were; 18(27.7%) 3TC/AZT/
NVP and least 3(6.8%) 3TC/TDF/NVP while 9(45%) 3TC/
AZT/LPV/r and 1(5%) DDI/ABC/LPV/r were on second-
line (Table 2).
Of the 44 patients on first-line, 18 (40.9%) had devel-
oped drug resistance mutations. The most common NRTI
mutation was M184V 12 (66.7%) of the 18 patients who
were infected with drug resistance strains. The K65R mu-
tation occurred in two patients without TAMs in combin-
ation with M184V mutations among those on TDF
containing first-line drugs. Of the 6 patients who har-
boured TAMs mutations, only 3 of them had T215Y mu-
tations while 3 had K70R mutations among those who
were on or on a previous AZT treatment. Nevertheless,
these two mutational pathways did not occur both in a
single patient (Table 3).
The NNRTI mutation profiles differed between patients
failing EFV compared to those on NVP containing regi-
mens. The K103N 11(61.1%) was most common NNRTI
mutations with highest frequency occurring on EFV (n = 6;
60%) than NVP (n = 4; 40%). Nevertheless, this occurrence
was not any significant different (p = 0.31).
EFV seemed to select for a wider range of mutations
compared to NVP (Table 2). Of the selected NNRTI mu-
tations, majority of them occurred in 3TC containing
regimen (Table 2).
Of the 20 patients failing second line drugs 6 patients
harboured drug resistance mutations. These mutations
were M184V (n = 1), T215Y (n = 2), V106A (n = 1), A98G
(n = 1), Y18C1C (n = 1), G190A (n = 1) and V108IV (n = 1).
However four patients had diverse drug mutations combi-
nations of K103N and V108IV (n = 1); Y184V, G190A andT215Y (n = 1); K103N, M184V and T215Y (n = 1); and
A98G, Y181C (n = 1) mutations. Single occurring muta-
tions of V106A occurred as expected in a patient who had
NVP regimen.
Table 2 Non nucleoside RT inhibitor (NNRTI) resistance mutations: percentages occurrence in patients treated with duo
nucleoside RT inhibitor plus NNRTI first -line antiretroviral (ARV) regimens
ARV Regimen n. 103 106 181 188 190 A98 V108 Y184 K70
NNRTI NRTI NS M C LCH ASEQ G IV V KT
60 n (%) n (%) n (%) n (%) n (%) n (%)
Efavenz (EFV) containing regiments
EFV TDF/3TC 3 1 - 1 (33.3) - 1 (33.3) 1 (33.3) 1 (33.3)
AZT/3TC 15 5 (33.3) - - - -
Sub-Total 18 6 (30) - 1 (5.6) - 1 (5.6)
Nevirapine (NVP) containing regiments
NVP D4T/3TC 4 - - - - - -
TDF/3TC 3 2 (66.7) - - - 1 (33.3) -
AZT/3TC 18 1 (11.1) - - 1 (5.6) 2 (11.1) -
Sub-Totals 25 3 (19.2) - - 1 (3.8) 3 (11.5) -
PI
Lopinavir (LPV)/Ritinovir containing regiments
LPV/R ABC/DDI 1 - - 1 (100) - - 1 (100)
ABC/3TC 2 - - - - - -
AZT/3TC 7 - - - - - -
AZT/DDI 5 1 (20) 1 (20) - - - - 1 (20)
TDF/ABC 2 1 (50) - - 1 (50) - 1
Sub-Totals (n =%) 17 2 (10) 1 (5) 1 (5) - 2 (10) 1 (5) 2
Totals 60 11 (18.3) 1 (1.6) 2 (3.2) 1 (1.6) 6 (9.4) 1 (1.6) 1 (1.6) 1 (1.6) 1 (1.6)
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From the 64 samples that were successfully amplified
and sequenced, analysis of the sequences showed that
the majority belonged to HIV subtype A 35/64 (54.5%)
followed by subtype D 17/64 (26.7%), subtype C 8/64
(12.5%) and CRF AE 3/64 (4.7%).
Discussion
In this study, among patients who had virological failure
with known NNRTI and NRTI mutations, those on first
and second-line therapy were 40.9% and 30% respect-
ively. The mutation patterns observed in this study were
similar to those obtained in subtype B. The M184V was
the most predominant mutation followed K103N. These
findings were similar to those obtained from previous
studies in Kenya [17] suggesting a consistent increase in
exposure to this drug. Though most patients were on
3TC as first-line drug, majority of these patients failed
due to the selected of M184V mutation. In addition,
K103N mutation selected for NNRTI was also detected
with high frequency in combination with M184V. This
mutation is known to limit Nevirapine and Efavirenz drug
efficacy. These findings were similar to those obtained
from most poor resource settings [17-19]. Since over
73.4% patients were exposed to thymidine NRTIs and
Lamivudine, This explains the number of NRTI relatedmutations observed in this study. Nevertheless, the most
frequent mutations in RT were associated to lamivudine
and NNRTIs exposure, which confirms the low genetic
barrier of these drugs [20,21].
Of the patients on first-line, 45.5% of them had no
mutations associated with drug resistance similar to those
reported in 17% South Africa [7], 47.3% Kenya [17]. The
high rates could suggest possible better drug adherence or
occurrence of non-drug associated mutations and prob-
ably outside the target sites. Determination of the presence
of NAMs or TAMs drug resistance mutations among pa-
tients on first-line is usually conducted in predictive for
second-line drugs. For instance, in this study, a K65R mu-
tation was detected in two patients who were on TDF/
EFV treatment. This mutation tends to limit treatment
with DDI, tenofovir and abacavir if previously not exposed
[22]. This mutation also occurred in combination with
M184V thus reducing susceptibility to TDF and EFV [22].
Contrary to previous studies recorded high rates of TAMs,
this study had low TAMs rates also occurring singly signi-
fying tolerability of these drugs and better adherence.
The occurrence of NNRTI mutations varied depending
on the NVP and EFV regimen. Though patient were on
NVP or EFV they both selected, K103N, Y181C, A190S
mutations with mutations; Y188L, A190A detected on
those on NVP while Y184V, K70KT mutations on those
Table 3 Nucleoside RT inhibitor (NRTI) resistance mutations: percentages occurrence in patients treated with duo
nucleoside RT inhibitor plus NRTI first -line
ARV regimens n/60 NAMs nucleoside analogue mutations Thymidine analogue mutations
K65R 184 V T215Y K70R
NNRTI NRTI R Y/M T/Y R
n (%) n (%) n (%) n (%)
Efavenz (EFV) containing regiments
EFV TDF/3TC 3 1 (11.1) 1 (33.3) - 1 (33.3)
AZT/3TC 15 - 5 (33.3) 1 (6.7) 1 (6.7)
Total 18 1 (5.6) 6 (33.3) 1 (5.6) 2 (11.1)
Nevirapine (NVP) containing regiments
NVP D4T/3TC 4 - 2 (50) - 1 (9.1)
TDF/3TC 3 1 (10) 1 (10) -
AZT/3TC 18 - 3 (12.5) 2 (8.3) -
Totals 25 1 (3.8) 6 (24) 2 (7.7) 1 (3.8)
PI
Lopinavir (LPV)/Ritinovir containing regiments
LPV/R ABC/DDI 1 - - - -
ABC/3TC 2 - - - -
AZT/3TC 7 - - -
AZT/DDI 5 - - - -
TDF/ABC 2 - - 2 (100) -
AZT/TDF/3TC 1 - - - -
Sub Total 18 - 1 (5) 2 (10) -
Totals 60 2 (4.7) 13 (21.7) 5 (7.8) 3 (4.7)
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selected by NVP they were detected among those on EFV.
These mutations Y181C and G190A are known to reduce
susceptibility to Etravirine which could be used either for
second or third-line regimen [11].
However, among patients failing second-line, 70% pa-
tient harboured virus with no drug associated mutations.
This also suggested better patient’s adherence. In 20%
(6/20) patient harbouring drug resistance viral strains,
two patients had first TAMs mutation pathway of T215Y
and also with NAMs M184V mutations. For NNRTI muta-
tions, two patients had K103N and A190A. The observed
low rates of acquired drug resistance among patients failing
second-line suggested the currently used NRTI regimens
are still effective. It could be argued that the detected mu-
tations among patients on second line could be associated
with the effect of persistent of acquired HIV-1 drug resist-
ance mutations before switching to therapy.
Despite these findings, this study had limitations. The
cross-sectional study and single sampling approach could
not confirm virological failure or rule out blips, which can
occur even during effective treatment [17-24]. Based on
this study design, this study this finding could not be gen-
eralised to present the overall efficiency of the nationalART program. Nevertheless, the amplified partial reverse
transcriptase gene could present the entire pol gene that
that is targeted by currently used drugs. Early Warning In-
dicators are often required as indicated by for efficient fol-
low out of the ART and limitations of the development of
HIV drug resistance. However, this study did not capture
this data, including on length of time the patients were
put on the failing regimen.
Conclusion
This study detected minority complex drug resistance
profiles that are predictive of resistance to currently used
second-line NRTIs and NNRTIs regimens. Though the
currently used drugs are still effective, the accumulated
resistance strains observed in this study clearly shows
that emergence of HIV drug resistance will continue to
remain a priority while scaling up ART coverage.
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